Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OKN4395 |
Synonyms | |
Therapy Description |
Limited information is currently available on OKN4395, a putative EP2 and EP4 inhibitor (Jan 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OKN4395 | OKN-4395|OKN 4395 | Limited information is currently available on OKN4395, a putative EP2 and EP4 inhibitor (Jan 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors (INVOKE) | Recruiting | USA | 0 |